Pharming Group (NASDAQ:PHAR - Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $8.49, but opened at $9.04. Pharming Group shares last traded at $8.87, with a volume of 902 shares changing hands.
Wall Street Analysts Forecast Growth
Several research analysts recently commented on the stock. HC Wainwright restated a "buy" rating and set a $37.00 target price on shares of Pharming Group in a report on Tuesday. Jefferies Financial Group assumed coverage on Pharming Group in a research report on Monday, December 9th. They set a "buy" rating and a $14.00 price target on the stock. Finally, Oppenheimer cut their price objective on Pharming Group from $31.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, October 28th.
Check Out Our Latest Stock Report on Pharming Group
Pharming Group Trading Up 5.3 %
The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The business has a 50-day simple moving average of $8.28 and a two-hundred day simple moving average of $8.14. The stock has a market cap of $606.44 million, a price-to-earnings ratio of -34.38 and a beta of 0.05.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its stake in shares of Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 41,110 shares of the company's stock after buying an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 as of its most recent filing with the SEC. 0.03% of the stock is owned by hedge funds and other institutional investors.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
